ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Medication and Placebo Response in Major Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00229476
Recruitment Status : Completed
First Posted : September 29, 2005
Last Update Posted : November 7, 2016
Sponsor:
Collaborators:
Eli Lilly and Company
Pfizer
Massachusetts General Hospital
Information provided by:
University of California, Los Angeles

September 28, 2005
September 29, 2005
November 7, 2016
December 2003
March 2006   (Final data collection date for primary outcome measure)
depressive symptoms
Same as current
Complete list of historical versions of study NCT00229476 on ClinicalTrials.gov Archive Site
brain electrical activity (EEG)
Same as current
Not Provided
Not Provided
 
Study of Medication and Placebo Response in Major Depression
Not Provided
The primary purpose of the research study is to use recordings of brain electrical activity (through electroencephalogram, or EEG) and symptom measurements to determine whether patients are likely to show a response to medication or placebo treatment during a treatment trial for depression.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Depressive Disorder, Major
Drug: sertraline (Zoloft)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
Same as current
Not Provided
March 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical Diagnosis of Unipolar Major Depression

Exclusion Criteria:

  • Substance Abuse, Psychotic Disorder, History of Severe Head Trauma
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00229476
03-08-033
H6U-US-X002
04012549
Not Provided
Not Provided
Not Provided
Not Provided
University of California, Los Angeles
  • Eli Lilly and Company
  • Pfizer
  • Massachusetts General Hospital
Principal Investigator: Andrew F. Leuchter, M.D. University of California, Los Angeles
University of California, Los Angeles
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP